In the first placebo-controlled trial of vaporized cannabis for acute migraine, patients experienced greater relief from pain and other symptoms than those receiving a placebo. During a migraine attack, participants who inhaled a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) reported significant pain reduction and improvement in their most bothersome symptom within 2 hours of treatment. The findings suggest that a THC-CBD combination may offer a viable treatment option for acute migraine in patients who do not respond to standard therapies. The findings were presented at the American Headache Society  Annual Meeting 2025.